AFC Gamma, a commercial mortgage REIT, provides $10-100 million loans to state-licensed cannabis operators in the U.S. In 2025, it expands its 14-loan portfolio across 15 states, leveraging U.S. rescheduling to reduce banking barriers. Its diversified lending model positions AFC Gamma to capitalize on the $57 billion U.S. cannabis market, offering stable returns despite industry volatility. Visit www.afcgamma.com for more information.

The AdvisorShares Pure US Cannabis ETF tracks U.S.-focused cannabis companies, with top holdings like Curaleaf and Green Thumb. In 2025, with a 0.76% expense ratio, it benefits from Schedule III rescheduling, boosting investor interest. Its focus on cultivators and retailers positions YOLO to capture growth in the $57 billion U.S. market, offering diversified exposure. Visit www.advisorshares.com for more information.

Alliance Growers develops cannabis production and distribution through its Four Pillars strategy, focusing on cultivation and branding. In 2025, it leverages Canada's recreational market and U.S. rescheduling for export potential. Note: Verify trading status due to low liquidity. Its partnerships position Alliance to tap into the $200 billion global cannabis market, despite small-cap risks. Visit www.alliancegrowers.com for more information.

The Amplify Alternative Harvest ETF tracks global cannabis companies, with holdings like Tilray and Innovative Industrial Properties. In 2025, with a 0.75% expense ratio, it capitalizes on U.S. rescheduling and EU medical cannabis growth. Its diversified portfolio positions MJ to benefit from the $200 billion global market, appealing to investors seeking broad exposure. Visit www.amplifyetfs.com for more information.

American Cannabis Company offers consulting and cultivation solutions, including its "Her Highness" brand for female consumers. In 2025, it expands in Colorado, leveraging U.S. rescheduling to enhance licensing services. Its American Cultivator Company supports growers with equipment, positioning AMMJ to capitalize on the $57 billion U.S. market, despite penny stock volatility. Visit www.theamericancannabiscompany.com for more information.

American Green, a pioneer since 2009, focuses on cannabis cultivation, retail, and smart vending systems. In 2025, it expands branded products and vending solutions, leveraging U.S. rescheduling. With over 50,000 shareholders, its cultivation partnerships position it for the $200 billion global market, though penny stock risks persist. Visit www.americangreen.com for more information.

Aurora Cannabis, a global producer, focuses on medical and recreational cannabis in Canada and Europe. In 2025, it leverages stock momentum and Q2 results to expand EU medical sales. Its Whistler Medical Marijuana acquisition enhances premium offerings, positioning Aurora for the $200 billion market. Visit www.auroramj.com for more information.

Auxly Cannabis holds a 5% Canadian market share, producing premium vape and pre-roll products. In 2025, it leverages a 34% gross margin and $123.4 million debt conversion by Imperial Brands to expand. Auxly's innovative formats position it for Canada's recreational market and U.S. rescheduling growth. Visit www.auxly.com for more information.

Body and Mind cultivates and retails cannabis from its 20,000 sq. ft. Nevada facility. In 2025, it expands U.S. dispensaries, leveraging Schedule III rescheduling for medical cannabis access. Its focus on quality extracts positions it to meet demand in the $57 billion U.S. market, despite small-cap volatility. Visit www.bodyandmind.com for more information.

Botanix Pharmaceuticals develops cannabinoid-based treatments for skin conditions like acne. In 2025, it advances clinical trials, leveraging U.S. rescheduling to expand medical applications. Its pharmaceutical-grade products position Botanix to tap into the $200 billion global cannabis market, offering a unique medical sector play. Visit www.botanixpharma.com for more information.

Canopy Growth, a global leader, produces diversified cannabis products. In 2025, it leverages stock momentum and Q2 results to expand EU and U.S. medical cannabis via its $229 million Hexo acquisition. Canopy's scale positions it for the $57 billion U.S. market. Visit www.canopygrowth.com for more information.

The Cannabist Company operates 125 U.S. dispensaries and cultivation facilities. In 2025, despite stock fluctuations, its low price-to-sales ratio positions it for upside post-rescheduling. Brands like Seed & Strain target the $57 billion U.S. market, balancing growth with regulatory risks. Visit www.cannabistcompany.com for more information.

Chicago Atlantic, a commercial mortgage REIT, provides loans to U.S. cannabis operators, addressing banking constraints. In 2025, it expands its portfolio post-rescheduling, reducing IRS 280E tax burdens. Its focus on institutional lending positions REFI for stable returns in the $57 billion U.S. market. Visit www.chicagoatlanticrefi.com for more information.

Cresco Labs manages 70 U.S. dispensaries across 10 states. In 2025, it leverages Schedule III rescheduling to expand medical cannabis, targeting $1.3 billion in revenue. Its quality focus positions Cresco to capture share in the $57 billion U.S. market, despite regulatory hurdles. Visit www.crescolabs.com for more information.

Cronos Group, backed by Altria's $1.8 billion stake, invests in brands like PEACE NATURALS. In 2025, it expands its portfolio, leveraging U.S. rescheduling for medical cannabis sales. Despite past challenges, Cronos' diversification positions it for the $200 billion global market. Visit www.thecronosgroup.com for more information.

Curaleaf, the largest U.S. cannabis company by revenue ($1.3 billion), operates 150+ dispensaries. In 2025, stock momentum fuels medical and recreational expansion. Curaleaf's scale positions it to dominate the $57 billion U.S. market, despite valuation risks. Visit www.curaleaf.com for more information.

Delta 9 operates a 95,000 sq. ft. facility in Winnipeg, producing cannabis and grow pods. In 2025, stock momentum reflects penny stock trends. Delta 9's retail and wholesale channels position it for Canada's recreational market and U.S. rescheduling, despite volatility. Visit www.delta9.ca for more information.

Green Thumb operates 90 U.S. dispensaries, generating significant revenue. In 2025, it expands into Virginia, leveraging rescheduling for medical cannabis growth. Its innovation focus positions Green Thumb to capture share in the $57 billion U.S. market, balancing regulatory risks. Visit www.gtigrows.com for more information.

IM Cannabis focuses on medical cannabis in Israel and Germany, exiting Canada. In 2025, stock momentum and Q1 results drive EU expansion. IMC's data-driven approach positions it for growth in Europe's medical cannabis market, despite small-cap volatility. Visit www.imcannabis.com for more information.

Innovative Industrial Properties, a REIT, leases properties to U.S. cannabis operators, with significant market cap. In 2025, it expands its portfolio post-rescheduling, reducing banking barriers. Its stable dividends position IIPR as a low-risk play in the $57 billion U.S. market. Visit www.innovativeindustrialproperties.com for more information.

Jazz Pharmaceuticals develops cannabinoid-based medicines, including Epidiolex for epilepsy, via its $6.7 billion GW Pharmaceuticals acquisition. In 2025, it leverages U.S. rescheduling to expand medical applications, targeting neurological disorders. Jazz's pharmaceutical focus positions it for growth in the $200 billion global cannabis market. Visit www.jazzpharma.com for more information.

National Access Cannabis operates care centers and retail stores in Canada, providing access to licensed producers. In 2025, it explores U.S. opportunities post-rescheduling, focusing on patient education. Note: Verify trading status due to low liquidity. Its network positions NAC for Canada's market and global growth. Visit www.nationalaccesscannabis.com for more information.

OrganiGram, a Canadian producer, offers cannabis products. In 2025, it expands multi-province facilities, leveraging U.S. rescheduling for exports. OrganiGram's quality focus positions it for growth in the $200 billion global market, despite competitive pressures. Visit www.organigram.ca for more information.

SinglePoint acquires cannabis-related companies, offering mobile payments and CBD via SingleSeed. In 2025, it leverages U.S. rescheduling to expand blockchain-integrated dispensary solutions. Its diversified portfolio positions SinglePoint for the $57 billion U.S. market, though penny stock volatility remains a concern. Visit www.singlepoint.com for more information.

SNDL, a Canadian retailer and producer, operates 180+ stores. In 2025, it leverages restructuring to expand recreational sales, targeting U.S. entry post-rescheduling. SNDL's scale positions it for Canada's market and the $200 billion global industry, balancing growth with regulatory risks. Visit www.sndlgroup.com for more information.

SpeakEasy Cannabis produces premium cannabis on a 290-acre British Columbia facility. In 2025, it leverages Canada's recreational market and U.S. rescheduling for exports. Its legacy growing expertise positions SpeakEasy to meet demand in the $200 billion global market, despite competition. Visit www.speakeasygrowers.com for more information.

TerrAscend operates 30 U.S. dispensaries with brands like The Apothecarium. In 2025, its Ohio acquisition and rescheduling drive medical cannabis expansion, targeting $1 billion in revenue. TerrAscend's operations position it for the $57 billion U.S. market. Visit www.terrascend.com for more information.

Tilray, the largest cannabis company post-Aphria acquisition, operates globally. In 2025, its Hexo acquisition and U.S. rescheduling drive EU and U.S. expansion, targeting a $100 billion opportunity. Tilray's scale positions it to lead the $200 billion market. Visit www.tilray.com for more information.

Trulieve manages 190 U.S. dispensaries, primarily in Florida. In 2025, it leverages Schedule III rescheduling for medical cannabis, targeting $1.4 billion in revenue. Its patient access focus positions Trulieve to dominate the $57 billion U.S. market, despite state-level risks. Visit www.trulieve.com for more information.

Verano operates 140 U.S. dispensaries with premium brands. In 2025, it leverages rescheduling to expand sales, targeting $1.2 billion in revenue. Its vertical integration positions Verano to capture share in the $57 billion U.S. market, navigating regulatory uncertainties effectively. Visit www.verano.com for more information.

Village Farms, a low-cost greenhouse producer, exports medical cannabis from Canada to Germany, the U.K., and Australia. In 2025, Q3 sales doubled, leveraging rescheduling for U.S. entry. Its global focus positions Village Farms for the $200 billion market, balancing agricultural expertise with cannabis growth. Visit www.villagefarms.com for more information.

22nd Century Group uses biotechnology to modify cannabinoid levels in cannabis plants. In 2025, it leverages U.S. rescheduling to expand medical applications, targeting pharmaceutical markets. Its innovative approach positions 22nd Century for the $200 billion global market, though it faces R&D risks. Visit www.xxiicentury.com for more information.